|[January 25, 2013]
Cardiovascular Systems to Webcast Fiscal 2013 Second-Quarter Earnings Conference Call Wednesday, Jan. 30
ST. PAUL, Minn. --(Business Wire)--
Cardiovascular Systems, Inc. (CSI (News - Alert)) (Nasdaq: CSII) will host a live
webcast of its fiscal 2013 second-quarter conference call on Wednesday,
Jan. 30, 2013, at 3:45 p.m. CT (4:45 p.m. ET). David L. Martin,
president and chief executive officer, and Laurence L. Betterley, chief
financial officer, will discuss the company's results for its fiscal
second quarter ended Dec. 31, 2012, and its financial outlook. The
company will issue a post-market earnings release on Jan. 30.
To access the live webcast, go to the investor section of the company's
on the day of the conference call and click on the webcast icon. A
webcast replay will be available beginning at 5:45 p.m. CT the same day.
To participate in the conference call, dial (888) 680-0860 and enter
21740396. Please dial in at least 10 minutes prior to the call. To
pre-register for the call, log on to the following website: https://www.theconferencingservice.com/prereg/key.process key=PEGHRHLQB.
When joining the call, pre-registered participants can enter their PIN
code, and other participants can press *0 to reach the operator, or wait
on the line for operator assistance.
If you do not have access to the Internet and want to listen to an audio
replay of the conference call, dial (888) 286-8010 and enter access
number 63349889. The audio replay will be available beginning at 5:45
p.m. CT on Wednesday, Jan. 30, 2013, through 11 p.m. CT on Wednesday,
Feb. 6, 2013.
About Cardiovascular Systems, Inc.
Inc., based in St. Paul, Minn., is a medical device company focused on
developing and commercializing innovative solutions for treating
vascular and coronary disease. The company's Orbital Atherectomy Systems
treat calcified and fibrotic plaque in arterial vessels throughout the
leg in a few minutes of treatment time, and address many of the
limitations associated with existing surgical, catheter and
pharmacological treatment alternatives. The U.S. FDA granted 510(k)
clearance for the use of the Diamondback Orbital Atherectomy System in
August 2007. To date, nearly 100,000 of CSI's devices have been sold to
leading institutions across the United States. CSI has also commenced
its ORBIT II Investigational Device Exemption clinical trial to evaluate
the safety and effectiveness of its orbital technology in treating
coronary arteries. The coronary system is limited by federal law to
investigational use and is currently not commercially available in the
For more information, visit the company's website at www.csi360.com.
[ Satellite Spotlight's Homepage ]